Podolski-Renic A, Chigriai M, Jovanovic Stojanov S, Grozdanic M, Lupsic E, Nikolic I
Pharmaceutics. 2025; 17(2).
PMID: 40006556
PMC: 11859366.
DOI: 10.3390/pharmaceutics17020189.
Hwang Y, Kim M
Int J Mol Sci. 2025; 26(1.
PMID: 39796178
PMC: 11719884.
DOI: 10.3390/ijms26010322.
Mouery R, Lukasik K, Hsu C, Bonacci T, Bolhuis D, Wang X
Cell Rep. 2024; 43(8):114510.
PMID: 39018246
PMC: 11403584.
DOI: 10.1016/j.celrep.2024.114510.
Cizmecioglu O
Turk J Biol. 2023; 46(3):207-215.
PMID: 37529255
PMC: 10388040.
DOI: 10.55730/1300-0152.2609.
Tian X, He Y, Qi L, Liu D, Zhou D, Liu Y
Int J Biol Sci. 2023; 19(9):2817-2834.
PMID: 37324947
PMC: 10266079.
DOI: 10.7150/ijbs.79949.
Cell cycle exits and U-turns: Quiescence as multiple reversible forms of arrest.
Johnson M, Cook J
Fac Rev. 2023; 12:5.
PMID: 36923701
PMC: 10009890.
DOI: 10.12703/r/12-5.
Postmitotic G1 phase survivin drives mitogen-independent cell division of B lymphocytes.
Singh A, Spitzer M, Joy J, Kaileh M, Qiu X, Nolan G
Proc Natl Acad Sci U S A. 2022; 119(18):e2115567119.
PMID: 35476510
PMC: 9170024.
DOI: 10.1073/pnas.2115567119.
Repositioning of duloxetine to target pancreatic stellate cells.
Sagara A, Nakata K, Matsumoto S, Guan W, Shinkawa T, Iwamoto C
Oncol Lett. 2021; 22(4):744.
PMID: 34466156
PMC: 8387862.
DOI: 10.3892/ol.2021.13005.
DIscBIO: A User-Friendly Pipeline for Biomarker Discovery in Single-Cell Transcriptomics.
Ghannoum S, Leoncio Netto W, Fantini D, Ragan-Kelley B, Parizadeh A, Jonasson E
Int J Mol Sci. 2021; 22(3).
PMID: 33573289
PMC: 7866810.
DOI: 10.3390/ijms22031399.
A unified model for the G1/S cell cycle transition.
Hume S, Dianov G, Ramadan K
Nucleic Acids Res. 2020; 48(22):12483-12501.
PMID: 33166394
PMC: 7736809.
DOI: 10.1093/nar/gkaa1002.
Integrating Old and New Paradigms of G1/S Control.
Rubin S, Sage J, Skotheim J
Mol Cell. 2020; 80(2):183-192.
PMID: 32946743
PMC: 7582788.
DOI: 10.1016/j.molcel.2020.08.020.
PP2A and tumor radiotherapy.
Lei X, Ma N, Du L, Liang Y, Zhang P, Han Y
Hereditas. 2020; 157(1):36.
PMID: 32847617
PMC: 7450598.
DOI: 10.1186/s41065-020-00149-7.
Prognostic Impact of PPP2R5C Gene Expression in Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics.
El Taweel M, Gawdat R, Abdelfattah R
Indian J Hematol Blood Transfus. 2020; 36(1):37-46.
PMID: 32158086
PMC: 7042454.
DOI: 10.1007/s12288-019-01142-5.
STRIPAK Members Orchestrate Hippo and Insulin Receptor Signaling to Promote Neural Stem Cell Reactivation.
Gil-Ranedo J, Gonzaga E, Jaworek K, Berger C, Bossing T, Barros C
Cell Rep. 2019; 27(10):2921-2933.e5.
PMID: 31167138
PMC: 6581792.
DOI: 10.1016/j.celrep.2019.05.023.
Quiescence, an individual journey.
Sagot I, Laporte D
Curr Genet. 2019; 65(3):695-699.
PMID: 30649583
DOI: 10.1007/s00294-018-00928-w.
Ras signals principally via Erk in G1 but cooperates with PI3K/Akt for Cyclin D induction and S-phase entry.
Vasjari L, Bresan S, Biskup C, Pai G, Rubio I
Cell Cycle. 2018; 18(2):204-225.
PMID: 30560710
PMC: 6343710.
DOI: 10.1080/15384101.2018.1560205.
Activation of the oncogenic transcription factor B-Myb via multisite phosphorylation and prolyl cis/trans isomerization.
Werwein E, Cibis H, Hess D, Klempnauer K
Nucleic Acids Res. 2018; 47(1):103-121.
PMID: 30321399
PMC: 6326806.
DOI: 10.1093/nar/gky935.
Control of the Restriction Point by Rb and p21.
Moser J, Miller I, Carter D, Spencer S
Proc Natl Acad Sci U S A. 2018; 115(35):E8219-E8227.
PMID: 30111539
PMC: 6126733.
DOI: 10.1073/pnas.1722446115.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, OConnor C, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S
Sci Transl Med. 2018; 10(450).
PMID: 30021885
PMC: 8335581.
DOI: 10.1126/scitranslmed.aaq1093.
Mathematical modelling of reversible transition between quiescence and proliferation.
Pandey N, Vinod P
PLoS One. 2018; 13(6):e0198420.
PMID: 29856829
PMC: 5983510.
DOI: 10.1371/journal.pone.0198420.